R&D/Pipelines Report 2022: Innovating to turn the tide - The world’s leading COVID-19 vaccine and therapeutic manufacturers continue to develop treatments for the waves of variants as well as life-changing therapies for disease areas outside the world of coronaviruses. The world’s efforts to combat the global pandemic continue to evolve, as does Coronavirus Disease 2019 as variants and subvariants constantly toss volleys of grenades at the battlefront lines.
Amgen (AMGN), headquartered in Thousand Oaks, Calif., announced yesterday that its Phase III study of Vectibix (panitumumab) had met its primary endpoint in the treatment of chemorefractory wild-type KRAS (exon 2) metastatic colorectal cancer (mCRC). The study was designed to determine the survival benefit of Vectibix and best supportive care (BSC) in comparison to BSC […]
THOUSAND OAKS, Calif., June 18, 2015 /PRNewswire/ — Amgen (NASDAQ: AMGN) today announced that a Phase 3 study evaluating Vectibix® (panitumumab) and best supportive care (BSC) met its primary endpoint, demonstrating a statistically significant improvement in overall survival (OS) in patients with chemorefractory wild-type KRAS (exon 2) metastatic colorectal cancer (mCRC) compared to those patients treated with […]
Will good news and a stock surge mean Synergy Pharmaceuticals is soon to be a target for acquisition? Some analysts think so. Synergy Pharmaceuticals (SGYP) announced the top-line results from the first of two pivotal Phase III clinical trials studying two different plecanatide treatment doses in adult chronic idiopathic constipation (CIC). Plecanatide is being studied […]
R&D efforts on the part of major biopharmaceutical companies for novel drugs to treat depression and other CNS diseases have eroded over the past decade. In fact, a study published by the Rand Corporation referred to these as “neglected diseases”, a jarring comment when one considers how widespread these diseases are and that current treatments, […]
BioMarin Pharmaceutical Inc said its experimental drug was effective in improving growth in children with the most common form of dwarfism in a mid-stage study. The company’s shares rose 6.5 percent to $131 in after-hours trading on Wednesday. The drug, BMN 111 (vosoritide), was evaluated in children with achondroplasia, the most common form of dwarfism, […]
Scientists have discovered a new anti-malarial compound that could treat patients with a single $1 dose, including those with strains of the mosquito-borne disease that are resistant to current drugs. Although it is still years from reaching the market, results from tests conducted on human blood in the laboratory and in live mice suggest it […]
Allergan Plc, best known as the maker of Botox, announced today that it will buy Kythera Biopharmaceuticals, Inc. (KYTH) for approximately $2.1 billion. Kythera is focused on treatments for double chins and male pattern baldness. The deal for the Dublin-based Allergan Inc. (AGN) to pay about $75 per Kythera share. About 80 percent will be […]
Drugmakers’ plans to conduct vast clinical trials to test and hopefully validate the first Ebola vaccines have been thwarted by success in beating back the deadly epidemic in West Africa. GlaxoSmithKline, Merck and Johnson & Johnson are struggling to recruit volunteers with enough exposure to the disease to prove whether their vaccines are doing the […]
British drugmaker GlaxoSmithKline is investing $95 million to create a new U.S. research institute led by a top genomics professor to investigate how a cell’s operating system works. The move reflects a commitment to fundamental research by the British company, even as its shifts emphasis to greater reliance on non-pharmaceutical businesses such as consumer healthcare […]
GlaxoSmithKline wants to better understand biology so it can discover more medicines, like every other drugmaker. It also wants to quit wasting money on drug candidates that look promising in the lab, but flop years later when given to hundreds or thousands of real people. Today, London-based GSK is betting that one way around the […]